Motley Fool Press Release.
Scholar Rock Holding has seen its share price move sharply over recent years, which naturally raises a question for anyone looking at the stock today. Is the current US$44.18 price still grounded in the company’s book value, or has the market run ahead of what its balance sheet can reasonably support? Over the past 3 years the stock has returned about 252.3%, which puts a lot of pressure on the underlying book value to justify that kind of gain. The business relies heavily on the strength of...
Detailed price information for Strategy Inc (MSTR-Q) from The Globe and Mail including charting and trades.
CAMBRIDGE, Mass., October 08, 2026--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced it has resubmitted the Marketing Authorisation Application (MAA) for apitegromab for the treatment of children and adults with spinal muscular atrophy (SMA) to the European Medicines Agency (EMA).
Scholar Rock Holding (NASDAQ:SRRK) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Scholar Rock Holding (SRRK) has an average rating of buy and mean price target of $69.12, according
Scholar Rock Holding Corporation (NASDAQ:SRRK) secured FDA approval on September 11 for ISEMBYLD, apitegromab-mstn, to treat spinal muscular atrophy in adults and children aged two and older currently receiving survival motor neuron 2 (SMN2)-targeted therapy. Approval opens a commercial opportunity built around adding muscle-directed treatment to existing care. The investment question now shifts to how […]
FDA approval of Scholar Rock’s ISEMBYLD (apitegromab) for SMA drives a Strong Buy case, with $2B+ market upside and EU/JP catalysts. Click for more on SRRK stock.
Scholar Rock (SRRK) stock slides as Barclays downgrades the company despite FDA approval of its spinal muscular atrophy drug, Isembyld. Read more here.
Scholar Rock Holding (SRRK) has an average rating of buy and mean price target of $69.62, according
The U.S. Food and Drug Administration on Friday approved ISEMBYLD (apitegromab-mstn) from Scholar Rock for spinal muscular atrophy (SMA) in adults and pediatric patients aged 2 years and older. The decision makes ISEMBYLD the first muscle-targeted therapy to demonstrate motor...
Scholar Rock Holding Corp (NASDAQ:SRRK) shares rose 9. 1% in pre-market trading to $60.
This is the newest page. Registered accounts read further back.